Trademark Awarded for Primary Cell-Friendly Transfection Reagent, Nov 27, 2012
SAN DIEGO, Nov 27, 2012 -- The United States Patent and Trademark Office has awarded Cell Applications, Inc. trademark registration number 4,248,740 to Cytofect™.  The Transfection Reagents, a new class of unique chemical formulations specifically optimized for transfecting primary cells, offer high efficiency, viability and affordability with low toxicity in a complete system.  For researchers, the advancement overcomes technical and financial challenges for primary cell molecular delivery, such as expensive electroporation instruments or relatively toxic chemical formulations.  Cytofect™ Transfection Kits are plasmid DNA delivery systems specifically optimized to deliver DNA into a wide variety of cell types. The reagents provide exceptionally high post-transfection viabilities, and even after passaging, cells transfected with Cytofect™ continue to express transgenic protein. Each kit includes the primary cell-specific or cell line-specific Cytofect™ Transfection Reagent, a unique, efficiency-boosting enhancer, as well as optimized Growth and Transfection Media. Cytofect™ Kits are available for Chondrocytes, Endothelial Cells, Epithelial Cells, Fibroblasts, Hepatocytes, HUVEC, Preadipocytes, Neurons and Smooth Muscle Cells, as well as cell lines.